Mail slow? View this month’s issue, right online!
Our digital version is easy to share with colleagues. See this month’s issue and digital versions of previous issues too.
A one-on-one interview conducted by our editorial team with industry leaders in our market.
Easy-to-digest data for your business.
Shampoos, conditioners, colorants and styling products created by leading industry suppliers.
Creams, serums, facial cleansers and more created by leading suppliers to the skincare industry.
Detergents, fabric softeners and more created by leading suppliers to the fabric care industry.
Eyeshadows, lipsticks, foundations and more created by leading suppliers to the color cosmetics industry.
Bodywashes, and bar and liquid soaps created by leading suppliers to the personal cleanser industry.
Hard surface cleaners, disinfectants and more created by leading suppliers to the home care industry.
Eau de parfums and eau de toilettes, body sprays, mists and more created by leading suppliers to the fragrance industry.
UV lotions and creams, self-tanners and after-sun products created by leading suppliers to the suncare industry.
A detailed look at the leading US players in the global household and personal products industry.
A detailed look at the leading players outside the US in the global household and personal products industry.
Looking for a new raw material or packaging component supplier? Your search starts here.
When you need a new manufacturing partner or private label company, get started here.
Who owns that? To keep track of leading brands and their owners, click here.
An annual publication, Company Profiles features leading industry suppliers with information about markets served, products, technologies and services for beauty, pesonal care and home care.
New products and technologies from some of the brightest minds in the industry.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to the leading experts in the global household and personal products industry.
Comprehensive coverage of key topics selected by sponsors.
Detailed research on novel ingredients and other solutions for the global household and personal care industry.
Company experts explain what works and why.
Exclusive content created by our affiliates and partners for the household and personal care industry.
Exciting news releases from the household and personal care industry.
Our targeted webinars provide relevant market information in an interactive format to audiences around the globe.
Looking for a job in the household and personal care industry, search no further.
Get your products and services in front of thousands of decision-makers. View our print and online advertising options.
Follow these steps to get your article published in print or online
What are you searching for?
Adulterated and misbranded products found during inspections at three manufacturers.
By: Christine Esposito
February 27, 2019
The US FDA has posted new warning letters, including three sent to companies making personal care and OTC products. The warning letters were addressed to Pure Sourece, LLC; Proandre SL; and Shadow Holdings LLC (dba Bocchi Laboratories). The letter to Pure Source LLC, Doral FL followed an inspection of its drug manufacturing facility conducted from Feb. 8 to March 1, 2018, noting that there were significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. Because methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, Pure Source’s drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B), according to FDA. The inspection also revealed that the firm manufactures and distributes misbranded drugs labeled as homeopathic under section 503(b)(4) of the FD&C Act, 21 U.S.C. 353(b)(4). Pure Source, according to FDA, firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). FDA said it quality unit did not initiate an out-of-specification (OOS) investigation for a raw material with excessive microbial growth. In addition, it did not conduct a thorough investigation for drug products with failing assay results. For example, FDA said Pure Sourece, LLC used a raw material lot with a too-numerous-to-count result for total aerobic microbial count. The firm, according to FDA, was using the material in an acne treatment it was making for a customer. FDA said the firm failed to thoroughly investigate the excessive microbial contamination and distributed finished product made with the highly contaminated raw material. FDA said it released the failed lot of raw material, which was used in the manufacture of the finished drug product and failed to provide adequate corrective actions and preventive actions (CAPA). FDA alledges that the company did not identify the microorganisms to determine whether any were potentially pathogenic and failed to evaluate the consumer hazard posed by this microbial contamination, and that it decided that this ingredient batch did not need to conform to a microbial specification because it is from a natural mineral source. FDA also wrote in the letter addressed to Pure Source: “Notably, you also told our investigator that you informed the product owner about the failing result and the owner insisted on using the failing (b)(4) ingredient. Insistence from a customer does not relieve you from your obligation to follow CGMP regulations.” In addition, FDA said the firm’s quality unit released OOS drug products for distribution without conducting a thorough investigation, including avobenzone sunscreen drug product (Lot C06Z9), which had a failing assay result of 0.85%; and bulk in-process material Pain Relief Gel Lot which had a failing assay result of 2.47% w/w. FDA also issued a letter to Proandre SL of Barcelona, Spain following an section of its drug manufacturing facility in June 2018 for significant violations of CGMP regulations for finished pharmaceuticals. FDA also said that as formulated and labeled, the OTC drug products Proandre Antibacterial Soap Liquid and Proandre Hand Sanitizer Liquid are misbranded. FDA said Proandre failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)). It said the firm released Proandre Antibacterial Soap Liquid without testing for identity and strength. Our investigator documented that you only test your finished drug products for specific gravity, pH, refraction value, and microbiological tests. FDA also addressed the firm’s failure to follow an adequate written testing program designed to assess the stability characteristics of drug products. In a third letter, FDA said it conducted an inspection of Shadow Holdings LLC, dba Bocchi Laboratories of Santa Clarita, CA in response to an outbreak of Burkholderia cepacia associated with Medline Remedy Essentials Cleanser No-Rinse Foam, which the firm akes for use in hospital settings, and to determine your firm's compliance with the Federal Food, Drug, and Cosmetic Act (the Act). Based on its inspection, FDA said found significant violations of the Act. In its letter, FDA wrote: ‘Your firm is a contract manufacturer for various products, including no-rinse cleanser foam, face wash, lotion, moisturizer, hair styling cream, shampoo, and conditioner. These products that you manufacture, pack, and label are intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance, and as such, they are cosmetics within the meaning of section 201(i) of the Act [21 U.S.C. 321(i)]. The microbial contamination of the Medline Remedy Essentials Cleanser No-Rinse Foam product causes this product to be adulterated within the meaning of section 601(a) of the Act [21 U.S.C. 361(a)], as described further below. Furthermore, the conditions observed during the inspection cause Medline Remedy Essentials Cleanser No-Rinse Foam and other cosmetics manufactured in your facility to be adulterated within the meaning of section 601(c) of the Act [21 U.S.C. 361(c)], as described further below. It is a violation of Section 301(a) of the Act [21 U.S.C. 331(a)] to introduce or deliver for introduction into interstate commerce an adulterated cosmetic.” The Medline Remedy Essentials brand Cleanser No-Rinse Foam is adulterated, according to FDA. Under section 601(a) of the Act [21 U.S.C. 361(a)], a cosmetic is adulterated if it bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labeling thereof, or under such conditions of use as are customary or usual. FDA’s investigator collected samples of the Medline Remedy Essentials brand Cleanser No-Rinse Foam from lots Mo7247 and Mo6691 and these samples were found by FDA laboratory analysis to contain the pathogen Burkholderia cepacia, which may render the product injurious to health. FDA said that it acknowledged that company had recalled several cosmetics products due to potential microbiological contamination. (The firm initiated a recall on March 28, 2018, for Medline Remedy Essentials Cleanser No-Rinse Foam due to potential contamination with Burkholderia cepacian and also issued a second recall on May 8, 2018, for nineteen cosmetic products due to potential contamination with Burkholderia cepacia. Itinitiated a recall for Super Sculpt Glaze on December 11, 2018, for potential contamination with Burkholderia cepacia.) According to FDA, on March 29, 2018, April 23, 2018, April 26, 2018, and May 3, 2018, the FDA collected environmental swabs from the production area and product contact areas, as well as water samples. FDA laboratory analysis of these samples found contamination with Burkholderia cepacia, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonasfiuorescens, Pseudomonas oryzihabitans, other Pseudomonas spp., Enterobacter gergoviae, and several other microbiological organisms. These microorganisms in the water, production area, and other product contact areas could contaminate your cosmetic products, which may render them injurious to health. FDA said the firm released finished cosmetic products such as Remedy Essential No-Rinse Cleansing Foam that did not meet your finished product specification limits for Aerobic Plate Count (APC) of “(b)(4) cfu/ gm” and Yeast & Mold (Y&M) of “(b)(4) cfu/gm”. Specifically, your test results showed “TNTC” [Too Numerous to Count] for both Aerobic Plate Count and Yeast & Mold for two lots of Remedy Essential No-Rinse Cleansing Foam, but you released those two lots and did not investigate or identify the source of the elevated microbial counts. The warning letter also summarized significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, including Acne Shave Cream, Acne Shave Moisturizer and X-Jow Pain Gel. These products, according to FDA, are “drugs” as defined by section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or under section 201(g)(1)(C) of the Act [21 U.S.C. 321(g)(1)(C)], because they are intended to affect the structure or any function of the body. The letters can be accessed here.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !